About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
GRACE
cancergrace.org
Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
Factors for Positive Outcomes in Consolidative Therapies for NSCLC
By
GRACE
FEATURING
Julia Rotow
,
Puneeth Iyengar
,
Ticiana Leal
By
GRACE
FEATURING
Julia Rotow
,
Puneeth Iyengar
,
Ticiana Leal
0 views
January 31, 2023
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Featured Video
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
OncTalk 2022
04:04
GRACE
Studies in Chemoimmunotherapy for NSCLC
Feat.
C. Kim
04:29
GRACE
Dual Immune Checkpoint Blockade With or Without Chemotherapy for mNS…
Feat.
C. Kim
07:38
GRACE
How Does PD-L1 Score Affect Treatment Options for NSCLC
Feat.
S. Patel,
T. Leal,
P. Iyengar,
A. Desai,
C. Kim,
J. Rotow
06:29
GRACE
Strategies to Overcome Resistance in NSCLC
Feat.
A. Desai
09:47
GRACE
Overcoming Resistance in EGFR+ NSCLC
Feat.
A. Desai
03:46
GRACE
Overcoming Resistance in ALK+ or KRAS+ NSCLC
Feat.
A. Desai
02:28
GRACE
Preoperative vs. Postoperative NSCLC Treatment
Feat.
J. Rotow,
P. Iyengar,
T. Leal
03:48
GRACE
NSCLC Trials for Patients With Actionable Mutations and the Importan…
Feat.
J. Rotow,
P. Iyengar,
T. Leal
03:05
CancerGRACE
Factors for Positive Outcomes in Consolidative Therapies for NSCLC
Feat.
J. Rotow,
P. Iyengar,
T. Leal
11:50
GRACE
The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies
Feat.
J. Rotow
06:17
GRACE
Studies in Oligometastatic NSCLC: Current Data and Definitions
Feat.
P. Iyengar
06:19
GRACE
What Factors Determine a Successful Clinical Trial for NSCLC?
Feat.
P. Iyengar
07:11
CancerGRACE
Personalized Treatment for mNSCLC
Feat.
P. Iyengar
25:15
GRACE
Local Consolidative Therapy for Oligometastatic NSCLC: Ready for Pri…
Feat.
P. Iyengar
17:47
GRACE
Preoperative Chemoimmunotherapy for NSCLC
Feat.
J. Rotow
29:00
GRACE
Therapeutic Options in Driver-Mutation Positive mNSCLC Refractory to…
Feat.
A. Desai
18:41
GRACE
Frontline Treatment of Advanced NSCLC Without Actionable Driver Muta…
Feat.
C. Kim
